Key Takeaways NVO will report Q3 results on Nov. 5, with a focus on Ozempic and Wegovy's sales performance.Wegovy and Ozempic growth likely slowed due to weaker U.S. demand and market competition.Rybelsus, insulin, and Rare Disease product sales likely provided support to the top line.Novo Nordisk (NVO) is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Tog ...